MedTrace Logo

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

NCT06400459 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-02-12

Study results available
· View outcomes & findings →

Summary

Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.

Conditions

Interventions

DRUG

IVW-1001 Ophthalmic Eyelid Wipe 0.1%

IVW-1001 Ophthalmic Eyelid Wipe 0.1%

DRUG

IVW-1001 Ophthalmic Eyelid Wipe 0.2%

IVW-1001 Ophthalmic Eyelid Wipe 0.2%

DRUG

IVW-1001 Placebo

IVW-1001 Placebo

Sponsors & Collaborators

  • IVIEW Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Bo Liang, PhD · IVIEW Therapeutics Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-25
Primary Completion
2024-10-15
Completion
2024-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06400459 on ClinicalTrials.gov